Abstract | Objectives: Materials and Methods: We switched patients who had completed 24-month daily teriparatide treatment to denosumab (switch group, n=18) and compared their BMD every 6 months up to 48 months with the group who continued to receive denosumab ( denosumab group, n=16). Results: At 48 months, the lumbar spine BMD was significantly increased from baseline in both groups ( denosumab: 10.4 ± 8.7%, p<0.001; switch: 14.2 ± 6.8%, p<0.001). However, a significant increase in femoral neck BMD from baseline occurred only in the switch group (11.2 ± 14.6%, p<0.05); denosumab (4.1 ± 10.8%). The total hip BMD increased significantly from baseline in both groups ( denosumab: 4.60 ± 7.4%, p<0.05; switch: 7.2 ± 6.9%, p<0.01). Femoral neck BMD was significantly increased in the switch versus the denosumab group (p<0.05). Conclusion:
|
Authors | Yasuaki Hirooka, Yuji Nozaki, Saki Okuda, Masafumi Sugiyama, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura |
Journal | Frontiers in endocrinology
(Front Endocrinol (Lausanne))
Vol. 12
Pg. 753185
( 2021)
ISSN: 1664-2392 [Print] Switzerland |
PMID | 34646240
(Publication Type: Clinical Trial, Journal Article)
|
Copyright | Copyright © 2021 Hirooka, Nozaki, Okuda, Sugiyama, Kinoshita, Funauchi and Matsumura. |
Chemical References |
- Bone Density Conservation Agents
- Diphosphonates
- Glucocorticoids
- Teriparatide
- Denosumab
|
Topics |
- Aged
- Bone Density
- Bone Density Conservation Agents
(adverse effects, therapeutic use)
- Denosumab
(adverse effects, therapeutic use)
- Diphosphonates
(therapeutic use)
- Female
- Femur Neck
(diagnostic imaging)
- Glucocorticoids
(adverse effects)
- Hip
(diagnostic imaging)
- Humans
- Male
- Middle Aged
- Osteoporosis
(chemically induced, drug therapy)
- Prospective Studies
- Spine
(diagnostic imaging)
- Teriparatide
(adverse effects, therapeutic use)
|